Status:
RECRUITING
The Efficacy and Safety of PEGylated GH for the Treatment of Short Stature in Chinese Children-GLOBE Reg
Lead Sponsor:
Beijing Children's Hospital
Collaborating Sponsors:
University of Glasgow
Conditions:
Growth Hormone Treatment
Growth Disorders
Eligibility:
All Genders
Up to 18 years
Brief Summary
In order to further observe the long-term safety and effectiveness of real-world polyethylene glycol-recombinant human growth hormone(PEG-rhGH) treatment of GHD, idiopathic short stature, and SGA in c...
Detailed Description
A database registration study was developed to retrospectively analyze the efficacy and safety of polyethylene glycol recombinant human growth hormone injection in the treatment of slow growth in chil...
Eligibility Criteria
Inclusion
- Patients with endogenous growth hormone deficiency, Turner Syndrome, SGA, idiopathic short stature, etc. treated with polyethylene glycol recombinant human growth hormone injection
Exclusion
- Patients with serious heart and lung, blood system, malignant tumors and other diseases or systemic infections, immune function is low and Persons with mental illness;
Key Trial Info
Start Date :
August 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2029
Estimated Enrollment :
2600 Patients enrolled
Trial Details
Trial ID
NCT06037473
Start Date
August 1 2023
End Date
August 1 2029
Last Update
September 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Endocrinology, Genetics, Metabolism
Beijing, Beijing Municipality, China, 010